Physician profile
Dawn M Hezel
NPI 1053625236
$2,380.42
in general payments reported to CMS, 2019-2025
14 companies · $433 in 2025
The $433 reported for 2025 was more than what 90% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $250 · 2023: $950 · 2024: $623 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $376.88 | 2022-2023 | |
| Sobi, INC | $249.99 | 2023 | |
| Novo Nordisk INC | $236.87 | 2024-2025 | Wegovy |
| Alk-Abello, INC | $230.54 | 2024 | Odactra, Grastek, Ragwitek |
| Amgen INC. | $189.43 | 2025 | Krystexxa, Tepezza |
| Acadia Pharmaceuticals INC | $153.92 | 2024 | Daybue |
| Jazz Pharmaceuticals INC. | $149.99 | 2023 | |
| Spark Therapeutics, INC. | $125.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2025 | |
| Gilead Sciences, INC. | $119.99 | 2024 | Epclusa |
| Pfizer INC. | $110.50 | 2023 | |
| Abbvie INC. | $110.28 | 2023 | |
| Ironshore Pharmaceuticals INC. | $77.05 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Hezel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.